Saxenda^® (liraglutide) injection

Saxenda^® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia).

Prescribing Information

Safety Data Sheet

Search for Letters

Find documents for this product by entering your search terms in the box below.

Text

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.

Have a Question?

All fields required.

Your question (please be specific)

Educational Materials (for Physician Payment` Sunshine Act and state reporting purposes¹)

I am not a Physician² or a licensed healthcare professional in MA, VT, or DC.

I approve the receipt of reportable article(s).

Please send ONLY non-reportable information.

¹ As required by the Sunshine Act, Novo Nordisk will disclose to the Federal government the value of certain educational materials including articles/reprints provided to Physicians and this information may be made publicly available by CMS. Novo Nordisk will also report similar information for healthcare professionals licensed to practice in those states with reporting requirements.

² Sunshine Act defines Physician as a licensed MD, DO, dentist, podiatrist, optometrist, or chiropractor.

Submit

Saxenda® (liraglutide) injection

Search for Letters

Have a Question?

Have a Question?

Saxenda^® (liraglutide) injection